Tag Archives: sunshine law

HEALTH REFORM: CMS Holds First Teleconference Related to Sunshine Law for Pharmaceutical, Biotechnology, and Medical Device Companies

On March 24, 2011, the Centers for Medicare & Medicaid Services (“CMS”) held a teleconference,[1] titled “Transparency Reports and Reporting of Physician Ownership or Investment Interests.[2] During the teleconference, CMS provided interested parties with the opportunity to publicly comment on certain topics related to the implementation of Section 6002 of the Patient Protection and Affordable Care Act (“PPACA”). These topics included (1) additional forms and natures of payments and transfers of value to be considered by CMS for reporting; (2) accessibility to, and usability of, the reported data for consumers; and (3) mechanisms for accurate, efficient, and cost-effective reporting of data. CMS announced that “draft regulations” will be issued later this year and that interested parties would have the opportunity to also comment on these draft regulations. See “Federal Transparency Is Now a Reality: Challenges and Opportunities for Pharma, Devices, and PBMs” for an overview of Section 6002 of PPACA.

Read full article